Treffer: Therapeutic efficacy of in-vivo IL-12 plasmid delivery using microbubble-assisted ultrasound in a B16F10 mouse melanoma model: a proof of concept.

Title:
Therapeutic efficacy of in-vivo IL-12 plasmid delivery using microbubble-assisted ultrasound in a B16F10 mouse melanoma model: a proof of concept.
Authors:
Oujagir E; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France; Université de Tours, INSERM, CEPR U1100, 37032 Tours, France., Mousset C; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Roy M; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Ramdani Y; Université de Tours, INSERM, CEPR U1100, 37032 Tours, France., Schubnel V; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Boisseau C; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Marouillat S; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Thépault RA; Université d'Angers, Nantes Université, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers CRCI2NA U1307, 44007 Nantes, France(2)., Fouan D; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Tartu JY; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Bouakaz A; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Serrière S; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France., Gouilleux-Gruart V; Université de Tours, INSERM, CEPR U1100, 37032 Tours, France., Escoffre JM; Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, 37032 Tours, France. Electronic address: jean-michel.escoffre@univ-tours.fr.
Source:
International journal of pharmaceutics [Int J Pharm] 2026 Jan 10; Vol. 688, pp. 126446. Date of Electronic Publication: 2025 Nov 30.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE
Imprint Name(s):
Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
Contributed Indexing:
Keywords: Melanoma − interleukin-12; Microbubbles; Sonoporation − immunotherapy; Ultrasound
Substance Nomenclature:
187348-17-0 (Interleukin-12)
Entry Date(s):
Date Created: 20251202 Date Completed: 20251219 Latest Revision: 20251219
Update Code:
20251220
DOI:
10.1016/j.ijpharm.2025.126446
PMID:
41330438
Database:
MEDLINE

Weitere Informationen

In-vivo targeted delivery of immunostimulatory molecules for melanoma treatment is a promising strategy to overcome complexity, toxicity, and cost associated with current immunotherapies. Among these molecules, interleukine-12 (IL-12) is a potent immunostimulatory cytokine that plays a major role in antitumoral immune response. However, systemic administration of IL-12 induces severe side effects, highlighting the need for efficient and safe in-vivo delivery modalities. Microbubble-assisted ultrasound (MB-assisted US) is an emerging non-invasive and targeted method for therapeutic molecule delivery. This study aimed to evaluate its efficacy for intratumoral (i.t.) delivery of a plasmid encoding IL-12 (pIL-12) in a mouse melanoma model. In-vitro, delivery of 5 or 10 μg of pIL-12 into melanoma cell suspensions using MB-assisted US increased IL-12 concentration to 1429 ± 125 and 2352 ± 125 pg/mL, respectively, whereas pIL-12 treatment alone did not elicit IL-12 secretion. Similarly, acoustically mediated delivery of 10 or 50 μg of pIL-12 into melanoma spheroids significantly increased IL-12 concentration - 131 ± 7 and 250 ± 60 pg/mL respectively - compared to pIL-12 alone (0 pg/mL for 10 μg and 7.5 ± 7.5 pg/mL for 50 μg). In-vivo, acoustically mediated pIL-12 delivery increased serum mIL-12 concentration by 5-fold compared with i.t. pIL-12 injection alone, promoting NK cell recruitment and activation within the tumor microenvironment. By day 15, this strategy reduced tumor volume by 2.5-fold relative to i.t. pIL-12 alone and improved mouse health status. These findings confirm that MB-assisted US is a relevant modality for in-vivo delivery of immunostimulatory molecules in melanoma therapy.
(Copyright © 2025 Elsevier B.V. All rights reserved.)

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.